Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “MET Amplification”

49 trials

Showing 20 of 49 results

Large-scale testing (Phase 3)Ended earlyNCT04816214
What this trial is testing

Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Novartis Pharmaceuticals 6
Testing effectiveness (Phase 2)WithdrawnNCT05567055
What this trial is testing

Central Nervous System Efficacy of Capmatinib in NSCLC With Brain Metastases With cfDNA Positive MET Alterations

Who this might be right for
Non-small Cell Lung Cancer
Timothy Burns, MD, PHD
Not applicableUnknownNCT02002416
What this trial is testing

Prognostic Value and Clinical Pathology of c-MET Expression and Amplification in Gastric Carcinoma

Who this might be right for
Gastric Cancer
Sun Yat-sen University 200
Early research (Phase 1)Study completedNCT01472016
What this trial is testing

Study of ABT-700 in Subjects With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors
AbbVie (prior sponsor, Abbott) 74
Testing effectiveness (Phase 2)Study completedNCT02414139
What this trial is testing

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Novartis Pharmaceuticals 373
Testing effectiveness (Phase 2)Ended earlyNCT04515394
What this trial is testing

Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)

Who this might be right for
Colorectal Neoplasms
EMD Serono Research & Development Institute, Inc. 3
Testing effectiveness (Phase 2)Ended earlyNCT02132598
What this trial is testing

Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases

Who this might be right for
Non Small Cell Lung Cancer (NSCLC)Metastases to the Brain
Liza Villaruz, MD 5
Large-scale testing (Phase 3)Not Yet RecruitingNCT06908772
What this trial is testing

Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients

Who this might be right for
Recurrent or Metastatic NSCLC Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression
Shanghai JMT-Bio Inc. 390
Testing effectiveness (Phase 2)Looking for participantsNCT07196644
What this trial is testing

Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan

Who this might be right for
Solid Tumors Harboring MET Amplification
AbbVie 125
Testing effectiveness (Phase 2)Looking for participantsNCT07322783
What this trial is testing

Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification

Who this might be right for
EGFR Positive Non-small Cell Lung CancerMET Amplification
Qingdao Central Hospital 60
Testing effectiveness (Phase 2)UnknownNCT02499614
What this trial is testing

Crizotinib in Pretreated Metastatic Non-small-cell Lung Cancer With MET Amplification or ROS1 Translocation (METROS)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Fondazione Ricerca Traslazionale 80
Testing effectiveness (Phase 2)Study completedNCT02449551
What this trial is testing

Study of AZD6094 (Volitinib) in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Third-line Treatment

Who this might be right for
Advanced Gastric Adenocarcinoma
Samsung Medical Center 16
Testing effectiveness (Phase 2)Study completedNCT02435121
What this trial is testing

A Study Assessing Efficacy and Safety of SAR125844 in NSCLC Patients With MET Amplification

Who this might be right for
Neoplasm Malignant
Sanofi 1
Testing effectiveness (Phase 2)Looking for participantsNCT07087223
What this trial is testing

Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure

Who this might be right for
Non Small Cell Lung Cancer NSCLC
Peking University Cancer Hospital & Institute 42
Not applicableLooking for participantsNCT05703516
What this trial is testing

A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea

Who this might be right for
Non-Small-Cell Lung Carcinoma
Novartis Pharmaceuticals 250
Testing effectiveness (Phase 2)Looking for participantsNCT06574347
What this trial is testing

Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.

Who this might be right for
Non-Small-Cell Lung Cancer
Avistone Biotechnology Co., Ltd. 120
Large-scale testing (Phase 3)Active Not RecruitingNCT05015608
What this trial is testing

Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification

Who this might be right for
Non-small Cell Lung Cancer
Hutchison Medipharma Limited 250
Testing effectiveness (Phase 2)Looking for participantsNCT06343064
What this trial is testing

Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI

Who this might be right for
Non-Small-Cell Lung Cancer
Avistone Biotechnology Co., Ltd. 156
Early research (Phase 1)Active Not RecruitingNCT03333343
What this trial is testing

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

Who this might be right for
EGFR-mutant Non-small Cell Lung Cancer
Novartis Pharmaceuticals 105
Testing effectiveness (Phase 2)Ended earlyNCT04926831
What this trial is testing

Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC

Who this might be right for
Non-small Cell Lung Cancer
Novartis Pharmaceuticals 4
Load More Results

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation